Clara Leandro

Clara Leandro

Auto-generated profile, based on publicly available information

Clara Leandro

Technophage

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
Diane J OrdwayDiane J Ordway
Diane J Ordway
MVMiguel Viveiros
Miguel Viveiros
CLClara Leandro
Clara Leandro
RBRosário Bettencourt
Rosário Bettencourt
JAJosefina Almeida
Josefina Almeida
LALeonard Amaral
Leonard Amaral
The phenothiazines chlorpromazine (CPZ) and thioridazine (TZ) have equal in vitro activities against antibiotic-sensitive and -resistant Mycobacterium tuberculosis. These compounds have not been used as anti- M. tuberculosis agents because their in vitro activities take place at concentrations which are beyond those that are clinically achievable. In addition, chronic administration of CPZ produces frequent severe side effects. Because CPZ has been shown to enhance the killing of intracellular M. tuberculosis at concentrations in the medium that are clinically relevant, we have investigated whether TZ, a phenothiazine whose negative side effects are less frequent and serious than those associated with CPZ, kills M. tuberculosis organisms that have been phagocytosed by human macrophages, which have nominal killing activities against these bacteria. Both CPZ and TZ killed intracellular antibiotic-sensitive and -resistant M. tuberculosis organisms when they were used at concentrations in the medium well below those present in the plasma of patients treated with these agents. These concentrations in vitro were not toxic to the macrophage, nor did they affect in vitro cellular immune processes. TZ thus appears to be a serious candidate for the management of a freshly diagnosed infection of pulmonary tuberculosis or as an adjunct to conventional antituberculosis therapy if the patient originates from an area known to have a high prevalence of multidrug-resistant M. tuberculosis isolates. Nevertheless, we must await the outcomes of clinical trials to determine whether TZ itself may be safely and effectively used as an antituberculosis agent.

1 September 2002 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
Gabriela Santos-GomesGabriela Santos-Gomes
Gabriela Santos-Gomes
RRRicardo Rosa
Ricardo Rosa
CLClara Leandro
Clara Leandro
SCSofia Cortes
Sofia Cortes
PRPedro Romão
Pedro Romão
HSHenrique Silveira
Henrique Silveira

11 June 2013 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
JMJoão J. Mendes
João J. Mendes
CLClara Leandro
Clara Leandro
SCSofia Corte‐Real
Sofia Corte‐Real
RBRaquel Barbosa
Raquel Barbosa
PCPatrícia Cavaco‐Silva
Patrícia Cavaco‐Silva
MGMiguel Garcia
Miguel Garcia

1 August 2005 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MVMiguel Viveiros
Miguel Viveiros
AJAna Jesus
Ana Jesus
MBMafalda Brito
Mafalda Brito
CLClara Leandro
Clara Leandro
MMMarta Martins
Marta Martins
LALeonard Amaral
Leonard Amaral
Expression of eight transporter genes of Escherichia coli K-12 and its Δ acrAB mutant prior to and after induction of both strains to tetracycline resistance and after reversal of induced resistance were analyzed by quantitative reverse transcriptase PCR. All transporter genes were overexpressed after induced resistance with acrF being 80-fold more expressed in the Δ acrAB tetracycline-induced strain.

1 September 2002 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MVMiguel Viveiros
Miguel Viveiros
IPIsabel Portugal
Isabel Portugal
RBRosárIo Bettencourt
RosárIo Bettencourt
TVThomas C. Victor
Thomas C. Victor
AJAnnemarie M. Jordaan
Annemarie M. Jordaan
LALeonard Amaral
Leonard Amaral
An American Type Culture Collection reference strain and eight clinical strains of Mycobacterium tuberculosis , all of which were susceptible to isoniazid (INH) (mean MIC, 0.06 mg/liter) and negative for the Ser315Thr katG mutation, were left in their BACTEC 12B vials (for use with the BACTEC 460-TB method) containing 0.1 mg of INH per liter for periods of up to 28 days after the completion of the antibiotic susceptibility test. Each eventually grew to levels compatible with those of INH-resistant strains. Successive passages in INH-containing BACTEC 12B vials and onto solid media showed that the resistance noted above was maintained. Successive passages of these M. tuberculosis strains in which INH resistance had been induced into BACTEC 12B vials or solid media containing stepwise increases in INH concentrations eventually yielded organisms resistant to 20 mg of INH per liter. Transfer of cells in which INH resistance had been induced to drug-free medium followed by repeated passages in that medium eventually yielded organisms whose susceptibility to INH was identical to that of the original parent strains. The cycle of induced INH resistance could be repeated with these now INH-susceptible cells. The use of M. tuberculosis identification probes and IS 6110 -based restriction fragment length polymorphism analyses of cultures throughout the induction of INH resistance and the reversal of resistance in drug-free medium eliminated the possibility that the culture was contaminated or that the initial specimen had a mixed type of infection. Induced high-level resistance to INH (20 mg/liter) could be reduced 100-fold with a subinhibitory concentration of reserpine but not with verapamil. These results collectively suggest that high-level resistance to INH can be induced in INH-susceptible M. tuberculosis strains by the induction of a reserpine-sensitive efflux mechanism.

1 August 2014 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
JMJoão J. Mendes
João J. Mendes
CLClara Leandro
Clara Leandro
CMCarla Mottola
Carla Mottola
RBRaquel Barbosa
Raquel Barbosa
FSFilipa A. Silva
Filipa A. Silva
MGMiguel Garcia
Miguel Garcia
In patients with diabetes mellitus, foot infections pose a significant risk. These are complex infections commonly caused by Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii, all of which are potentially susceptible to bacteriophages. Here, we characterized five bacteriophages that we had determined previously to have antimicrobial and wound-healing potential in chronic S. aureus, P. aeruginosa and A. baumannii infections. Morphological and genetic features indicated that the bacteriophages were lytic members of the family Myoviridae or Podoviridae and did not harbour any known bacterial virulence genes. Combinations of the bacteriophages had broad host ranges for the different target bacterial species. The activity of the bacteriophages against planktonic cells revealed effective, early killing at 4 h, followed by bacterial regrowth to pre-treatment levels by 24 h. Using metabolic activity as a measure of cell viability within established biofilms, we found significant cell impairment following bacteriophage exposure. Repeated treatment every 4 h caused a further decrease in cell activity. The greatest effects on both planktonic and biofilm cells occurred at a bacteriophage : bacterium input multiplicity of 10. These studies on both planktonic cells and established biofilms allowed us to better evaluate the effects of a high input multiplicity and a multiple-dose treatment protocol, and the findings support further clinical development of bacteriophage therapy.